{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:27Z","timestamp":1785186507805,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.blre.2021.100889","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T11:31:04Z","timestamp":1631187064000},"page":"100889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["T time: Emerging and new therapies for peripheral T-cell lymphoma"],"prefix":"10.1016","volume":"52","author":[{"given":"Alain","family":"Mina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100889_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CCO.0000000000000469","article-title":"New perspectives in the therapeutic approach of peripheral T-cell lymphoma","volume":"30","author":"Gisselbrecht","year":"2018","journal-title":"Curr. Opin. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11899-018-0432-3","article-title":"The future of combination therapies for peripheral T cell lymphoma (PTCL)","volume":"13","author":"Ma","year":"2018","journal-title":"Curr. Hematol. Malig. Rep. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0015","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0020","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0025","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol. [internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0030","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood [Internet]"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2021.100889_bb0035","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","article-title":"CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma?","volume":"12","author":"Kim","year":"2001","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0045","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"D\u2019Amore","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2021.100889_bb0050","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2021.100889_bb0055","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","author":"Savage","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100889_bb0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0065","series-title":"Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study","first-page":"4150","author":"Lansigan","year":"2016"},{"key":"10.1016\/j.blre.2021.100889_bb0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14737140.8.3.413","article-title":"Histone deacetylase inhibitors in lymphoma and solid malignancies","volume":"8","author":"Rasheed","year":"2008","journal-title":"Expert Rev. Anticancer Ther. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J. Hematol. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0085","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet. Haematol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0090","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100889_bb0095","series-title":"Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma","author":"E. B","year":"2020"},{"key":"10.1016\/j.blre.2021.100889_bb0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J. Hematol. Oncol. [internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0105","article-title":"A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"103","author":"Strati","year":"2018","journal-title":"Haematologica [internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0110","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem. [internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0115","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br. J. Haematol. [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0120","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP phase 1 trial","volume":"126","author":"Johnston","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100889_bb0130","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0135","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/jco.2015.33.15_suppl.8521","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma: activity in T-cell lymphoma","volume":"33","author":"Mehta-Shah","year":"2015","journal-title":"J Clin. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0140","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100889_bb0145","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood.V128.22.2991.2991","article-title":"A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas","volume":"128","author":"Mehta-Shah","year":"2016","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12185-015-1738-8","article-title":"Multistep tumorigenesis in peripheral T cell lymphoma","volume":"102","author":"Sakata-Yanagimoto","year":"2015","journal-title":"Int. J. Hematol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cas.13393","article-title":"Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma","volume":"109","author":"Fukumoto","year":"2018","journal-title":"Cancer Sci. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0160","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.clml.2019.07.444","article-title":"New insights into the molecular pathogenesis of T-cell lymphomas","volume":"19","author":"Gaulard","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0165","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0170","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br. J. Haematol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0180","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/cancers11030421","article-title":"Novel therapies and approaches to relapsed\/refractory HL beyond chemotherapy","volume":"11","author":"Mina","year":"2019","journal-title":"Cancers (Basel). [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pathog.2016.02.002","article-title":"Biology of peripheral T cell lymphomas \u2013 not otherwise specified: is something finally happening?","volume":"3","author":"Maura","year":"2016","journal-title":"Pathogenesis [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0195","first-page":"316","article-title":"Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas","volume":"118","author":"Weiss","year":"1985","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.blre.2021.100889_bb0200","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0205","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0210","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0215","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0220","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0225","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0230","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother. Pharmacol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0240","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-04-2263","article-title":"Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density","volume":"11","author":"Niwa","year":"2005","journal-title":"Clin. Cancer Res. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0245","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685.014k26_685_690","article-title":"Expression pattern of T-cell\u2013associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0250","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2147\/OTT.S165615","article-title":"Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma","volume":"12","author":"Ollila","year":"2019","journal-title":"Onco. Targets Ther. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0255","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.blre.2021.100889_bb0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-08-1808","article-title":"Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia\/lymphoma","volume":"15","author":"Nakagawa","year":"2009","journal-title":"Clin. Cancer Res. [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0265","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol. [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0270","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol. [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0275","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0280","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nri3403","article-title":"T cell receptor signalling networks: branched, diversified and bounded","volume":"13","author":"Brownlie","year":"2013","journal-title":"Nat. Rev. Immunol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0285","article-title":"Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules","volume":"4","author":"So","year":"2013","journal-title":"Front. Immunol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0290","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.hoc.2019.04.002","article-title":"Peripheral T-cell lymphoma: moving toward targeted therapies","volume":"33","author":"Ng","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am. [internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0295","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1084\/jem.20070366","article-title":"Phosphoinositide 3\u2013kinase \u03b3 participates in T cell receptor\u2013induced T cell activation","volume":"204","author":"Alc\u00e1zar","year":"2007","journal-title":"J. Exp. Med. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0300","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0305","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, Phase 1 combination studies with expansion cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0310","series-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: Dose optimization efficacy update and expansion phase initial results. 2020 ASH Annual Meeting & Exposition. Abstract 44","author":"Pro","year":"2020"},{"key":"10.1016\/j.blre.2021.100889_bb0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","article-title":"Aurora A kinase (AURKA) in normal and pathological cell division","volume":"70","author":"Nikonova","year":"2013","journal-title":"Cell. Mol. Life Sci. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0320","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","article-title":"Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma","volume":"21","author":"Zullo","year":"2015","journal-title":"Clin. Cancer Res. [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0325","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of Aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin. Cancer Res. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0330","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma \u00a8","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2021.100889_bb0335","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V122.21.368.368","article-title":"High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients","volume":"122","author":"Redaelli","year":"2013","journal-title":"Blood [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.blre.2021.100889_bb0350","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/blood-2019-125507","article-title":"First-in-human study of the EZH1\/2 dual inhibitor Valemetostat in relapsed or refractory non-Hodgkin lymphoma (NHL) - updated results focusing on adult T-cell leukemia-lymphoma (ATL)","volume":"134","author":"Morishima","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100889_bb0355","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med. [Internet]."},{"key":"10.1016\/j.blre.2021.100889_bb0360","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma. Myeloma Leuk"},{"key":"10.1016\/j.blre.2021.100889_bb0370","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/cancers10090339","article-title":"Current immunotherapeutic approaches in T cell non-hodgkin lymphomas","volume":"10","author":"Poggio","year":"2018","journal-title":"Cancers (Basel). [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0375","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Invest. [Internet]"},{"key":"10.1016\/j.blre.2021.100889_bb0380","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.blre.2021.100889_bb0385","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000187","article-title":"Rapid and durable complete remission of refractory AITL with azacitidine treatment in absence of TET2 mutation or concurrent MDS","volume":"3","author":"Gregory","year":"2019","journal-title":"HemaSphere."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:25:41Z","timestamp":1759436741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":76,"alternative-id":["S0268960X21000953"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100889","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T time: Emerging and new therapies for peripheral T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100889"}}